
News|Articles|July 21, 2020
AstraZeneca and IQVIA Partner on Potential COVID-19 Vaccine
Author(s)Pharmaceutical Technology Editors
The project will focus on providing a faster route to clinical studies for AstraZeneca’s potential COVID-19 vaccine, AZD1222.
Advertisement
AstraZeneca and IQVIA, a Durham, NC-based advanced analytics and technology solutions provider, announced they are teaming up to develop a potential new vaccine for COVID-19 as part of the US government’s Operation Warp Speed project.
The project will focus on providing a faster route to clinical studies for AstraZeneca’s potential COVID-19 vaccine, AZD1222, according to a July 14, 2020 press release. The initiative will also include a subject study which will utilize IQVIA’s virtual trial solutions.
Source:
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
What the OSTP’s New Policy Blueprint Means for Pharma Manufacturing and Development
2
Triple-Negative Breast Cancer Deal Signals Oncology Licensing Shift
3
H1 2026 in Review: AI Adoption, Onshoring, and Data Gaps
4
Is Organizational Readiness Pharma's Real AI Barrier in 2026?
5




